Archimed to Buy Esperion Therapeutics for Up to $1.1 Billion

Dow Jones

05/01

By Robb M. Stewart

Healthcare-focused investment firm Archimed is buying commercial-stage biopharmaceutical company Esperion Therapeutics for as much as $1.1 billion.

Esperion said Friday it has reached a definitive agreement that will see funds managed by Archimed pay shareholders $3.16 a share in cash, and offer the right to participate in milestone payments of up to $100 million tied to future sales performance. The upfront cash consideration represents a premium of 58% to Esperion's closing price a day earlier.

Esperion, which was founded in 2008, is focused on bringing new medicines to market and offers solutions to combat the risk of cardiovascular disease.

Chief Executive Sheldon Koenig said Archimed's acquisition offers Esperion shareholders with attractive and immediate upfront value while preserving the opportunity to see additional upside tied to future growth of the company's core cardiometabolic products.

Esperion's board unanimously approved the transaction and is recommending that shareholders vote their shares to approve the deal.

When the takeover is completed, Esperion will become a privately held company and its shares will no longer be listed on Nasdaq. The stock was halted in premarket trading.

Write to Robb M. Stewart at robb.stewart@wsj.com

(END) Dow Jones Newswires

May 01, 2026 07:29 ET (11:29 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2632812611"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2632812611\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2632812611?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-01 19:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2632812611","market":"hk","top_or_hot":-1,"title":"Archimed to Buy Esperion Therapeutics for Up to $1.1 Billion","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Robb M. Stewart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Healthcare-focused investment firm Archimed is buying commercial-stage biopharmaceutical company Esperion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for as much as $1.1 billion. \n</p>\n<p>\n  Esperion said Friday it has reached a definitive agreement that will see funds managed by Archimed pay shareholders $3.16 a share in cash, and offer the right to participate in milestone payments of up to $100 million tied to future sales performance. The upfront cash consideration represents a premium of 58% to Esperion's closing price a day earlier. \n</p>\n<p>\n  Esperion, which was founded in 2008, is focused on bringing new medicines to market and offers solutions to combat the risk of cardiovascular disease. \n</p>\n<p>\n  Chief Executive Sheldon Koenig said Archimed's acquisition offers Esperion shareholders with attractive and immediate upfront value while preserving the opportunity to see additional upside tied to future growth of the company's core cardiometabolic products. \n</p>\n<p>\n  Esperion's board unanimously approved the transaction and is recommending that shareholders vote their shares to approve the deal. \n</p>\n<p>\n  When the takeover is completed, Esperion will become a privately held company and its shares will no longer be listed on Nasdaq. The stock was halted in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 01, 2026 07:29 ET (11:29 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Archimed to Buy Esperion Therapeutics for Up to $1.1 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArchimed to Buy Esperion Therapeutics for Up to $1.1 Billion\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-05-01 19:29</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Robb M. Stewart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Healthcare-focused investment firm Archimed is buying commercial-stage biopharmaceutical company Esperion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for as much as $1.1 billion. \n</p>\n<p>\n  Esperion said Friday it has reached a definitive agreement that will see funds managed by Archimed pay shareholders $3.16 a share in cash, and offer the right to participate in milestone payments of up to $100 million tied to future sales performance. The upfront cash consideration represents a premium of 58% to Esperion's closing price a day earlier. \n</p>\n<p>\n  Esperion, which was founded in 2008, is focused on bringing new medicines to market and offers solutions to combat the risk of cardiovascular disease. \n</p>\n<p>\n  Chief Executive Sheldon Koenig said Archimed's acquisition offers Esperion shareholders with attractive and immediate upfront value while preserving the opportunity to see additional upside tied to future growth of the company's core cardiometabolic products. \n</p>\n<p>\n  Esperion's board unanimously approved the transaction and is recommending that shareholders vote their shares to approve the deal. \n</p>\n<p>\n  When the takeover is completed, Esperion will become a privately held company and its shares will no longer be listed on Nasdaq. The stock was halted in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 01, 2026 07:29 ET (11:29 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ESPR","symbol_name":"Esperion Therapeutics Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2632812611","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2632812611","pubTimestamp":1777634940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Healthcare-focused investment firm Archimed is buying commercial-stage biopharmaceutical company Esperion Therapeutics for as much as $1.1 billion.Esperion said Friday it has reached a definitive agreement that will see funds managed by Archimed pay shareholders $3.16 a share in cash, and offer the right to participate in milestone payments of up to $100 million tied to future sales performance. The upfront cash consideration represents a premium of 58% to Esperion's closing price a day earlier.Esperion, which was founded in 2008, is focused on bringing new medicines to market and offers solutions to combat the risk of cardiovascular disease.Chief Executive Sheldon Koenig said Archimed's acquisition offers Esperion shareholders with attractive and immediate upfront value while preserving the opportunity to see additional upside tied to future growth of the company's core cardiometabolic products.Esperion's board unanimously approved the transaction and is recommending that shareholders","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ESPR":"Esperion Therapeutics Inc.","BK4007":"制药"},"translate_title":"Archimed将以高达11亿美元收购Esperion Therapeutics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ESPR":1.5},"content_text":"By Robb M. Stewart \n\n\n \n\n\n  Healthcare-focused investment firm Archimed is buying commercial-stage biopharmaceutical company Esperion Therapeutics for as much as $1.1 billion. \n\n\n  Esperion said Friday it has reached a definitive agreement that will see funds managed by Archimed pay shareholders $3.16 a share in cash, and offer the right to participate in milestone payments of up to $100 million tied to future sales performance. The upfront cash consideration represents a premium of 58% to Esperion's closing price a day earlier. \n\n\n  Esperion, which was founded in 2008, is focused on bringing new medicines to market and offers solutions to combat the risk of cardiovascular disease. \n\n\n  Chief Executive Sheldon Koenig said Archimed's acquisition offers Esperion shareholders with attractive and immediate upfront value while preserving the opportunity to see additional upside tied to future growth of the company's core cardiometabolic products. \n\n\n  Esperion's board unanimously approved the transaction and is recommending that shareholders vote their shares to approve the deal. \n\n\n  When the takeover is completed, Esperion will become a privately held company and its shares will no longer be listed on Nasdaq. The stock was halted in premarket trading. \n\n\n \n\n\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 01, 2026 07:29 ET (11:29 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}